Balchem Corporation · NASDAQ:BCPC

Balchem — BMO Farm to Market Investor Conference 2020

29 slides from Balchem's conference presentation, May 14, 2020

  1. Slide 1: BMO Farm to Market Investor Conference

    BMO Farm to Market Investor Conference May 14th, 2020 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • We will attempt to identify these statements by use of words such as expect, believe, anticipate, intend, and other words that denote fu

  3. Slide 3: Balchem Corporation

    Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place Highlights • NASDAQ: BCPC • Founded in 1967 • Headquarters: New Hampton, NY • Approximately 1,400 Employees • 21 Manufacturing Sites: - 17 in North America - 3 in Europe -

  4. Slide 4: Leadership

    Leadership Ted Harris, Chairman and CEO • Joined Balchem in May 2015 • Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years • Independent director and member of the Board of Directors of Pentair plc. • MBA from Harvard University and bache

  5. Slide 5: Balchem at a Glance

    Balchem at a Glance OTHER 4% SPECIALTY PRODUCTS 14% 82% HUMAN NUTRITION & HEALTH Nutrition & Health (% of FY 2019 sales) 54% ANIMAL NUTRITION & HEALTH 28% 82% Of Revenues Focused On Nutrition And Health 5

  6. Slide 6: Segment Overview

    Segment Overview Segment Markets Served Solutions 4% 14% Human Nutrition • Nutritional Supplements • Micro-encapsulation 82% & Health • Food and Beverage • Choline Nutrition & Health (% of sales) 54% • Infant & Toddler Formula • Chelated Minerals 28% • Organic Cereal • Powder, Flavor, & Cereal Syste

  7. Slide 7: Vision and Mission

    Vision and Mission Our vision is clear; to make the world a healthier place Our mission is to build a global nutrition and health company delivering trusted, innovative, and science based solutions to our customers Committed To Building A Global Nutrition And Health Company 7

  8. Slide 8: Strategic Focus

    Strategic Focus • Strengthening Positions in Attractive, Growing Markets – Building scale, adding adjacent capabilities, expanding market and geographic reach, broadening our portfolio of solutions, investing in new science, enabling market awareness • Driving Organic Growth – Creating new demand th

  9. Slide 9: Balchem Growth Platforms

    Balchem Growth Platforms Human Nutrition & Health Animal Nutrition & Health HUMAN NUTRITION & HEALTH ANIMAL NUTRITION & HEALTH • Leveraging Synergies Across Segment • ReaShure® Penetration • FDA RDI for Choline and Expanded Choline • NRC Recommendation on Choline Awareness / Science • Rumen Protecte

  10. Slide 10: Growth Vectors

    Growth Vectors Growth over 5 years Key Platforms Driving Growth Above Market • Choline and Mineral Nutrition for Mother & Child, Adult Cognition, Energy & Fitness, Liver Health, Diabetes Complications • ReaShure® Penetration Strategic Acquisitions • Rumen Protected Delivery Systems • Companion Anima

  11. Slide 11: COVID-19 Pandemic Response Update

    COVID-19 Pandemic Response Update • Uncertainty created by the coronavirus and its disruption on economic activity • Sales challenged by weaker demand in; – food services – animal protein markets including dairy protein – medical device sterilization due to fewer elective surgeries – lower fracking

  12. Slide 12: Q1 2020 Financial Summary

    Q1 2020 Financial Summary Sales Adj. EBITDA Adj. Net Earnings Adj. EPS ($M) ($M) ($M) ($/share) Up 11.1% Up 6.8% Up 11.4% Up 11.0% 42.4 0.81 174.4 39.7 26.4 157.0 23.7 0.73 1Q19 1Q20 1Q19 1Q20 1Q19 1Q20 1Q19 1Q20 • Growth in all Segments • Gross Margin% • Lower tax rate (19.3% in • Near Flat share c

  13. Slide 13: Historical Financials

    Historical Financials SALES ($M) ADJ. EBITDA ($M) 644 644 159 160 149 148 595 140 541 552 553 122 2014 2015 2016 2017 2018 2019 2014 2015 2016 2017 2018 2019 ADJ. NET EARNINGS ($M) ADJ. EPS ($/share) 3.19 104 3.01 98 2.51 2.52 2.53 80 80 82 2.21 69 2014 2015 2016 2017 2018 2019 2014 2015 2016 2017 2

  14. Slide 14: Segment Financials

    Segment Financials SALES ($M) ADJ. EBITDA ($M) 159 160 644 644 149 5 26 148 10 595 51 3 140 7 552 553 48 92 541 7 39 76 32 25 32 54 122 73 32 Other 105 70 28 54 178 Other 19 176 SP 54 158 37 29 33 33 166 161 SP 25 35 ANH 176 ANH 30 341 347 80 84 83 316 78 297 71 278 HNH 206 HNH 48 2014 2015 2016 201

  15. Slide 15: Capital Allocation Strategy and M&A

    Capital Allocation Strategy and M&A Capital Allocation Strategy Annual Cash Flow ($M) and Debt Leverage Ratio • Prioritize organic growth investments • Augment organic growth with targeted M&A 2.3x 1.1x 0.6x 124 • Pay Down Debt 1.5x 1.6x 1.2x 119 108 111 104 • Continue to pay and grow dividend 85 •

  16. Slide 16: Recent Acquisitions

    Recent Acquisitions Rationale Key Offering Zumbro River Brand Market consolidation and expanded High protein extrusion and December 2019 product offering agglomeration Chemogas Adds leadership position in Europe to Ethylene Oxide re-packaging and May 2019 already existing U.S. leadership distributio

  17. Slide 17: Free Cash Flow Conversion

    Free Cash Flow Conversion 130% Free Cash Flow as % of Non-GAAP Net Income 120% 110% 105% 105% 102% 102% 100% 93% 90% 79% 80% 70% 60% 50% 2014 2015 2016 2017 2018 2019 Free Cash Flow Conversion Solid Free Cash Flow Conversion, Turning Profits Into Cash 17

  18. Slide 18: Dividends

    Dividends • Yearly double-digit dividend growth for the last decade • Consistency in execution 0.52 0.47 0.42 0.38 0.34 0.30 ($/share) 0.26 0.22 0.18 0.15 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Consistent Dividend Policy 18

  19. Slide 19: Our Sustainability Framework

    Our Sustainability Framework Every day, Balchem is delivering trusted solutions that enhance health and well-being through science. The two objectives of our sustainability strategy directly support our mission of making the world a healthier place: • providing innovative solutions for the health an

  20. Slide 20: Our Sustainability Framework

    Our Sustainability Framework People Planet Profit 10.7 billion – number of animals reached per year 24.7% – revenue from products developed in the past 1.4 billion – number of people reached per year five years 0.59 GJ – energy intensity (GJ of energy per ton of 1.32 – total recordable injury rate (

  21. Slide 21: What Makes Balchem Unique?

    What Makes Balchem Unique? Proven Track Record Of Growth Protected Positions ✓ Proven ability to grow in in all economic ✓ Consolidated position in Choline conditions ✓ EPA Registrations for EO and PO ✓ Steady and thoughtful capital allocation ✓ Patent portfolio and premium branded ✓ Continued innov

  22. Slide 22: Summary / Wrap Up

    Summary / Wrap Up • Leading Positions in Attractive Markets • Creating New Demand Through Innovation • Delivering Healthy Margins • Generating Cash Flow from Operations Available for Reinvestment • Proven Track Record Reasons To Invest 22

  23. Slide 23: Confidential

    - baichem * Solve Today. Shape Tomorrow. Confidential 23

  24. Slide 24: Appendix

    Appendix 24

  25. Slide 25: Non-GAAP Financial Information

    Non-GAAP Financial Information Non-GAAP Financial Information In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding a

  26. Slide 26: Non-GAAP Financial Information - Continued

    Non-GAAP Financial Information - Continued 26

  27. Slide 27: Non-GAAP Financial Information - Continued

    Non-GAAP Financial Information - Continued 27

  28. Slide 28: Non-GAAP Financial Information - Continued

    Non-GAAP Financial Information - Continued 28

  29. Slide 29: Non-GAAP Financial Information - Continued

    Non-GAAP Financial Information - Continued 29

Balchem — BMO Farm to Market Investor Conference 2020 on 6ix